Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $1079.28
http://www.fool.com/investing/general/2015/12/05/these-3-etfs-jumped-in-november.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_c...
http://www.fool.com/investing/general/2015/11/30/last-weeks-top-healthcare-etf.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_cam...
http://www.fool.com/investing/general/2015/11/22/3-biotech-stocks-to-buy-in-december.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&u...
http://www.fool.com/investing/general/2015/11/01/the-top-3-biotech-etfs-on-the-market.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc...
http://www.fool.com/investing/general/2015/05/31/improve-your-diversification-strategy-with-these-3.aspx?source=eptadnlnk0000002
http://www.fool.com/investing/high-growth/2015/05/09/a-stock-market-bubble-in-biotech-stocks.aspx?source=eptadnlnk0000002
http://www.fool.com/investing/beginning/2015/04/19/how-to-invest-money-in-biotech.aspx?source=eptadnlnk0000002
http://www.fool.com/investing/etf/2015/03/31/these-3-etfs-are-crushing-the-market-in-2015.aspx?source=eptadnlnk0000002
http://www.fool.com/investing/general/2015/03/23/3-biotech-stocks-to-buy-if-the-sector-crashes.aspx?source=eptadnlnk0000002
State Street Global Advisors (SSGA) announced today that the SPDR® S&P Biotech ETF (NYSE: XBI), received payment as an authorized claimant...
Despite the rocky start and a plethora of technical issues, the Affordable Care Act (often known as Obamacare) saw a surge in enrollment in the...
The hot and the soaring biotechnology corner of the broad U.S. healthcare market suffered the steepest decline since October 2011 in...
The Q4 2013 earnings season has seen a weak start but is gradually showing impressive numbers that could touch the all-time quarterly high. The...
2013 was a great year for the U.S. equity markets which returned more than 30%. And with political deadlock averted and the U.S. economy regaining...
The Affordable Care Act—often known as Obamacare—has faced an incredible amount of scrutiny over the past few years. First, the law...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.